However, we observed higher concentrations of S-IgG and S-IgA, as well as more durable S-IgA in subjects that had previous antigen exposure through prior-infection, suggesting an advantage of multiple vaccine-doses analogous to the multiple vaccine-exposure, unlike the single-dose regimen for the Ad26.COV2.S vaccine used in this study. This evidence concerns the gene CD79A and infection.